These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17786395)

  • 1. [Pathogenesis of systemic sclerosis].
    Fabri M; Krieg T
    Hautarzt; 2007 Oct; 58(10):838, 840-3. PubMed ID: 17786395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current pathophysiological aspects of systemic sclerosis].
    Krieg T; Hunzelmann N
    Z Rheumatol; 2006 Jul; 65(4):275-8. PubMed ID: 16807741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Systemic sclerosis].
    Ihn H
    Nihon Rinsho; 2009 Mar; 67(3):519-22. PubMed ID: 19280926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
    Chujo S; Shirasaki F; Kawara S; Inagaki Y; Kinbara T; Inaoki M; Takigawa M; Takehara K
    J Cell Physiol; 2005 May; 203(2):447-56. PubMed ID: 15605379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
    Yamamoto T
    Arch Dermatol Res; 2006 Feb; 297(8):333-44. PubMed ID: 16402183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
    Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunopathological disturbances in systemic sclerosis].
    Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
    Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling.
    Wei J; Ghosh AK; Chu H; Fang F; Hinchcliff ME; Wang J; Marangoni RG; Varga J
    Arthritis Rheumatol; 2015 May; 67(5):1323-34. PubMed ID: 25707573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis.
    Mauch C; Kreig T
    Rheum Dis Clin North Am; 1990 Feb; 16(1):93-107. PubMed ID: 2406813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways as novel therapeutic targets in systemic sclerosis.
    Trojanowska M; Varga J
    Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis.
    Kissin E; Korn JH
    Curr Rheumatol Rep; 2002 Apr; 4(2):129-35. PubMed ID: 11890878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connective tissue metabolism including cytokines in scleroderma.
    Smith EA
    Curr Opin Rheumatol; 1992 Dec; 4(6):869-77. PubMed ID: 1457283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis.
    Distler JH; Jüngel A; Pileckyte M; Zwerina J; Michel BA; Gay RE; Kowal-Bielecka O; Matucci-Cerinic M; Schett G; Marti HH; Gay S; Distler O
    Arthritis Rheum; 2007 Dec; 56(12):4203-15. PubMed ID: 18050252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transforming growth factor-beta and its receptors in scleroderma].
    QIAN H; ZHENG M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):415-21. PubMed ID: 19693982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic sclerosis: pathophysiology of a multifaceted disease].
    Servettaz A; Agard C; Tamby MC; Guilpain P; Guillevin L; Mouthon L
    Presse Med; 2006 Dec; 35(12 Pt 2):1903-15. PubMed ID: 17159716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast abnormalities in the pathogenesis of systemic sclerosis.
    Usategui A; del Rey MJ; Pablos JL
    Expert Rev Clin Immunol; 2011 Jul; 7(4):491-8. PubMed ID: 21790292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts.
    Sato M; Shegogue D; Gore EA; Smith EA; McDermott PJ; Trojanowska M
    J Invest Dermatol; 2002 Apr; 118(4):704-11. PubMed ID: 11918720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible role for transforming growth factor-beta in systemic sclerosis.
    Smith EA; LeRoy EC
    J Invest Dermatol; 1990 Dec; 95(6 Suppl):125S-127S. PubMed ID: 2258629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenesis of systemic sclerosis.
    LeRoy EC
    Clin Exp Rheumatol; 1989; 7 Suppl 3():S135-7. PubMed ID: 2691149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.